Temocillin
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Temocillin.png | |
| Temocillin
| |
| Systematic (IUPAC) name | |
| (2S,5R,6S)-6-[(Carboxy-3-thienylacetyl)amino]- 6-methoxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0] heptane-2-carboxylic acid, | |
| Identifiers | |
| CAS number | |
| ATC code | J01 |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Temocillin | |
|
Articles | |
|---|---|
|
Most recent articles on Temocillin | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Temocillin at Clinical Trials.gov Clinical Trials on Temocillin at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Temocillin
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Temocillin Discussion groups on Temocillin Patient Handouts on Temocillin Directions to Hospitals Treating Temocillin Risk calculators and risk factors for Temocillin
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Temocillin | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Temocillin is a β-lactamase resistant penicillin marketed by Eumedica Pharmaceuticals as Negaban® primarily for the treatment of multiresistant Gram negative bacteria.
Pharmacology
Temocillin is a β-lactamase resistance penicillin. It is not active against Gram positive bacteria or bacteria with altered penicillin-binding proteins.
It is normally active against Moraxella catarrhalis, Brucella abortus, Burkholderia cepacia, Citrobacter species, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Pasteurella multocida, Proteus mirabilis, Salmonella typhimurium and Yersinia enterocolitica. It is also active against some Enterobacter species, Morganella morganii, and Serratia species. Temocillin has no useful activity against Gram positive organisms, Acinetobacter species, or Pseudomonas aeruginosa.
Its primary use is against Enterobacteriaceae, and in particular against strains producing extended spectrum β-lactamase or AmpC β-lactamase (Livermore, 2005).
Dosage
The common dosage is 1g intravenously or intramuscularly every 12 hours. For severe infections, the dose is 2g intravenously every 12 hours. There are good theoretical reasons for giving Temocillin as a continuous intravenous infusion in severe disease (Claeysoone, 2005): a single loading dose of 2g is given intravenously followed by a 4g infusion over 24 hours. Temocillin for intravenous injection is diluted in 20ml of sterile water; it is diluted in less than 2.7ml of sterile water when being prepared for intramuscular injection; the continuous infusion is diluted in 48ml of sterile water for ease of administration (1ml per half hour). To reduce pain, the intramuscular injection may be made up using sterile 1% lignocaine instead of sterile water.
Temocillin may be given to patient with impaired renal function. No adjustment needs to be made to the dose in mild to moderate renal impairment (creatinine clearance greater than 30ml/min). The manufacturer does not recommend using reduced doses, instead they recommend increasing the duration between doses. In severe renal impairment when it is 10 to 30, the dose is 1g in 24 hours; when less than 10, the dose is 1g every 48 hours. Temocillin is cleared by haemodialysis, which means that in dialysis patients, the dose should be given after dialysis.
There is no licensed oral preparation of Temocillin.
Undesirable effects
The undesirable effects of Temocillin are those of any β-lactam antibiotic. In particular, Temocillin has been associated with angioedema and anaphylaxis in penicillin allergic patients. Animal studies have not shown any induction of Clostridium difficile infection (Boon, 1985). As with any other penicillin, convulsions can occur if very high doses are given.
References
- Eumedica. Eumedica Pharmaceuticals. Retrieved on November 20, 2005.
- Bonacorsi S et al (1999). "Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis". Antimicrob Agents Chemother 43 (2): 213–7.
- Boon RJ et al (1985). "Studies with temocillin in a hamster model of antibiotic-associated colitis". Antimicrob Agents Chemother 27 (6): 980–1.
- Livermore DM et al (2005) Activity of temocillin vs. prevalent ESBL- and AmpC-producing Enterobacteriaceae from SE England. FIS Meeting, November 2005, Cardiff, UK
- Claeysoone K et al (2005) Continuous vs. Intermittent infusion of Temocillin in ICU patients. 25th ISICEM, March 2005, Brussels, Belgium, poster A351
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
